Article info

Download PDFPDF

Review
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects

Authors

  1. Correspondence to Professor Josef S Smolen; josef.smolen{at}meduniwien.ac.at
View Full Text

Citation

Smolen JS, Caporali R, Doerner T, et al
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects

Publication history

  • Received February 18, 2021
  • Revision received April 12, 2021
  • Accepted April 18, 2021
  • First published June 7, 2021.
Online issue publication 
June 07, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.